Every material Form 8-K Regeneron Pharmaceuticals filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Regeneron reported third quarter 2025 total revenues of $3.75 billion, up 1% from a year earlier, and GAAP diluted EPS of $13.62, up 18%. Non-GAAP diluted EPS fell 5% to $11.83, and EYLEA franchise U.S. net sales declined 28% to $1.11 billion, while the company narrowed or lowered several full-year 2025 expense guidance ranges and raised its GAAP effective tax rate guidance to approximately 14%.
Total revenues $3.754 billion vs. $3.721 billion in Q3 2024; Dupixent global net sales recorded by Sanofi rose 27% to $4.86 billion.
GAAP net income rose 9% to $1.460 billion, helped by $578 million in net gains on securities; non-GAAP net income fell 12% to $1.287 billion.
Full-year 2025 guidance: GAAP R&D and non-GAAP SG&A ranges lowered; GAAP effective tax rate raised to approximately 14% from 11%–13%.
Board declared a $0.88 per share dividend payable December 5, 2025; $2.156 billion remained available for share repurchases as of September 30, 2025.
Regeneron said its preliminary third quarter 2025 GAAP and non-GAAP results will include an acquired in-process research and development charge of about $83 million before taxes. The charge mainly relates to the previously disclosed $80 million up-front payment to Hansoh Pharmaceuticals under a 2025 license agreement, and is expected to reduce net income per diluted share by about $0.68. The figures are unaudited and not yet final, so actual results could differ.
Expected acquired IPR&D charge of about $83 million pre-tax for the quarter ended September 30, 2025
Charge mainly relates to the $80 million up-front payment to Hansoh Pharmaceuticals Group under the 2025 license agreement
Expected impact of about $0.68 per diluted share on both GAAP and non-GAAP net income
Results are preliminary and subject to financial statement closing procedures
Regeneron reported second quarter 2025 total revenues of $3.68 billion, up 4% from a year earlier, and GAAP earnings per diluted share of $12.81, up 3%. GAAP net income fell 3% to $1.39 billion, and the company raised its full-year 2025 GAAP effective tax rate guidance to 11%–13%.
Total revenues $3.68 billion, up 4%; GAAP net income $1.39 billion, down 3%
Non-GAAP EPS $12.89, up 12%; GAAP EPS $12.81, up 3%
2025 GAAP effective tax rate guidance raised to 11%–13% from 9%–11%; non-GAAP tax rate guidance unchanged at 11%–13%
Company expects delays to pending FDA approvals for EYLEA HD with August 2025 PDUFA dates; FDA issued a Complete Response Letter for odronextamab on July 30, 2025
Regeneron reported first quarter 2025 total revenues of $3.03 billion, down 4% from a year earlier, driven by a 20% drop in net product sales, mainly EYLEA. GAAP diluted EPS rose 16% to $7.27, while non-GAAP diluted EPS fell 14% to $8.22, and the company lowered its full-year 2025 gross margin guidance.
Total revenues $3.03 billion vs. $3.15 billion in Q1 2024; Sanofi collaboration revenue rose 30% to $1.18 billion.
Non-GAAP diluted EPS $8.22 vs. $9.55 a year earlier (down 14%); GAAP diluted EPS $7.27 vs. $6.27 (up 16%).
2025 guidance: GAAP gross margin on net product sales cut to 83%–84% from 84%–85%; non-GAAP to 86%–87% from 87%–88%; capital expenditures narrowed to $850–$950 million.
Repurchased $1.052 billion of stock in Q1 2025; $3.874 billion remained under repurchase programs as of March 31, 2025; quarterly dividend of $0.88 per share payable June 6, 2025.
Regeneron reported fourth-quarter 2024 revenue of $3.79 billion, up 10% from a year earlier, but GAAP diluted EPS fell 21% to $8.06 on unrealized losses on equity securities. Full-year 2024 revenue rose 8% to $14.20 billion and GAAP diluted EPS rose 10% to $38.34. The board started a quarterly cash dividend of $0.88 per share and added a $3.0 billion buyback, bringing total repurchase capacity to about $4.5 billion.
Q4 2024 GAAP net income was $918 million, down 21%; non-GAAP diluted EPS was $12.07, up 2%
Full-year 2024 GAAP net income was $4.413 billion, up 12%, and total revenue was $14.20 billion, up 8%
Dividend of $0.88 per share is payable March 20, 2025 to holders of record on February 20, 2025
Share repurchase capacity is about $4.5 billion after the new $3.0 billion program; the company repurchased $976 million of stock in Q4 2024
Regeneron released preliminary, unaudited fourth-quarter and full-year 2024 figures at the J.P. Morgan Healthcare Conference, showing aggregate U.S. EYLEA net product sales of $6 billion for the year, up 1%. The company also expects a fourth-quarter acquired in-process R&D charge of approximately $14 million pre-tax, which it says will reduce GAAP and non-GAAP net income per diluted share by about $0.11, and notes that results have not been finalized.
EYLEA HD and EYLEA aggregate U.S. net product sales were $6 billion for 2024, up 1%, and $1.5 billion in the fourth quarter of 2024 (preliminary, unaudited).
Expected fourth-quarter 2024 acquired IPR&D charge of approximately $14 million pre-tax, primarily related to asset acquisitions.
The charge is expected to lower GAAP and non-GAAP net income per diluted share for Q4 2024 by approximately $0.11.
Libtayo exceeded $1 billion in 2024 annual net sales, according to the press release.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Regeneron Pharmaceuticals filing is on SEC EDGAR ↗. 8-K briefs of other companies →